India accounts for 1 in 7 adults living with diabetes globally. An estimated 89.8 million adults aged 20-79 years in India ...

"Dapagliflozin inhibits renal glucose reabsorption, promotes urinary excretion, and works independently of insulin action of secretion," Dr. Henry said during the presentation.

The SGLT2 inhibitor dapagliflozin was associated with a reduced risk for hospitalization due to any cause in patients with chronic kidney disease with and without type 2 diabetes, according to a ...

During follow-up, the primary outcome occurred in 16.4% of participants in the dapagliflozin group and 19.5% of participants in the placebo group, for an HR of 0.82 (95% CI, 0.73-0.92; P < .001).

Dapagliflozin is a novel, selective, sodium glucose co-transporter 2 (SGLT2) inhibitor, currently being evaluated in Phase 3 trials as a once-daily oral therapy for the treatment of type 2 diabetes.

PHILADELPHIA, PA—Dapagliflozin added to optimal medical therapy results in meaningful improvements in symptoms and health-related quality of life in heart failure patients with reduced ejection ...

Individuals treated with dapagliflozin demonstrated a reduction in FPG, a secondary endpoint, from baseline at week 24: -12.5 mg/dL for dapagliflozin 2.5 mg, -18.8 mg/dL for dapagliflozin 5 mg and ...

Whatever the mechanism of benefit from dapagliflozin (Farxiga) in patients with heart failure (HF), the drug — and potentially also other sodium-glucose cotransporter 2 (SGLT2) inhibitors ...

Gains from adding dapagliflozin to SOC treatment for HFrEF were seen in the additional life-years and QALYs gained, along with cost per QALY gained (incremental cost-effectiveness ratio [ICER]).

Dapagliflozin, an oral SGLT2 inhibitor, decreased the risk of progression of focal segmental glomerulosclerosis compared with placebo, a subgroup analysis of the DAPA-CKD trial showed.